|
No records
|
|
163 |
Wahyuningsih R., Adawiyah R., Sjam R., Prihartono J., Ayu Tri Wulandari E., Rozaliyani A., Ronny R., Imran D., Tugiran M., Siagian F.E., Denning D.W. |
6507268400;57208658742;23398458200;6602605635;57224979940;57203065912;57224981604;57203976849;57218291154;57205685972;57223404509; |
Serious fungal disease incidence and prevalence in Indonesia |
2021 |
Mycoses |
64 |
10 |
|
1203 |
1212 |
|
1 |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85108784112&doi=10.1111%2fmyc.13304&partnerID=40&md5=5f442b4c8248caad9f19e8d0d684dd18 |
Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Parasitology, Universitas Kristen Indonesia, School of Medicine, Jakarta, Indonesia; Department of Community Medicine Universitas Indonesia, Faculty of Medicine, Jakarta, Indonesia; Department of Dentistry, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Department of Neurology, Universitas Indonesia, Faculty of Medicine/Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Manchester Fungal Infection Group, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom |
Wahyuningsih, R., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Department of Parasitology, Universitas Kristen Indonesia, School of Medicine, Jakarta, Indonesia; Adawiyah, R., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Sjam, R., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Prihartono, J., Department of Community Medicine Universitas Indonesia, Faculty of Medicine, Jakarta, Indonesia; Ayu Tri Wulandari, E., Department of Dentistry, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Rozaliyani, A., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Ronny, R., Department of Parasitology, Universitas Kristen Indonesia, School of Medicine, Jakarta, Indonesia; Imran, D., Department of Neurology, Universitas Indonesia, Faculty of Medicine/Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Tugiran, M., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Siagian, F.E., Department of Parasitology, Universitas Kristen Indonesia, School of Medicine, Jakarta, Indonesia; Denning, D.W., Manchester Fungal Infection Group, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom |
Background: Indonesia is a tropical country, warm and humid, with numerous environmental fungi. Data on fungal disease burden help policymakers and clinicians. Objectives: We have estimated the incidence and prevalence of serious fungal diseases. Methods: We found all published and unpublished data and estimated the incidence and prevalence of fungal diseases based on populations at risk. HIV data were derived from UNAIDS (2017), pulmonary tuberculosis (PTB) data from 2013–2019, data on chronic pulmonary aspergillosis (CPA) were used to estimate CPA prevalence and likely deaths, COPD data from Hammond (2020), lung cancer incidence was from Globocan 2018, and fungal rhinosinusitis was estimated using community data from India. Results: Overall ~7.7 million Indonesians (2.89%) have a serious fungal infection each year. The annual incidence of cryptococcosis in AIDS was 7,540. Pneumocystis pneumonia incidence was estimated at 15,400 in HIV and an equal number in non-HIV patients. An estimated 1% and 0.2% of new AIDS patients have disseminated histoplasmosis or Talaromyces marneffei infection. The incidence of candidaemia is 26,710. The annual incidence of invasive aspergillosis was estimated at 49,500 and the prevalence of CPA is at 378,700 cases. Allergic bronchopulmonary aspergillosis prevalence in adults is estimated at 336,200, severe asthma with fungal sensitisation at 443,800, and fungal rhinosinusitis at 294,000. Recurrent vulvovaginal candidiasis is estimated at 5 million/year (15–50 years old). The incidence of fungal keratitis around 40,050. Tinea capitis prevalence in schoolchildren about 729,000. Conclusions: Indonesia has a high burden of fungal infections. © 2021 Wiley-VCH GmbH. |
aspergillosis; candidaemia; epidemiology |
acquired immune deficiency syndrome; adolescent; adult; AIDS patient; allergic bronchopulmonary aspergillosis; Article; atypical mycobacteriosis; candidemia; chronic infection; cryptococcosis; diabetic patient; disease association; disease burden; eye infection; female; fungal sinusitis; histoplasmosis; human; immunocompromised patient; incidence; Indonesia; invasive aspergillosis; keratomycosis; major clinical study; male; mycosis; nonhuman; Pneumocystis pneumonia; prevalence; recurrent infection; respiratory tract disease; severe asthma; skin infection; Talaromyces marneffei; tinea capitis; vagina candidiasis; acquired immune deficiency syndrome; AIDS related complex; candidemia; child; fungus; incidence; lung aspergillosis; middle aged; prevalence; young adult; mycosis; Acquired Immunod |
John Wiley and Sons Inc |
09337407 |
|
33971053 |
Article |
Q1 |
1130 |
3649 |
|
|
|
164 |
Prasetyono T.O.H. |
26646993900; |
Epinephrine one-per-mil tumescent solution in hand surgery: Review of experimental and clinical studies [Solution tumescente d’épinéphrine à un pour un million en chirurgie de la main: analyse des études expérimentales et cliniques] |
2021 |
Hand Surgery and Rehabilitation |
40 |
5 |
|
554 |
559 |
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85106494075&doi=10.1016%2fj.hansur.2021.04.013&partnerID=40&md5=b52780e0e5c85229435baa908f64e6c3 |
Division of Plastic Surgery, Department of Surgery, Cipto Mangunkusumo Hospital/Faculty of Medicine Universitas Indonesia, Jl. Diponegoro No. 71, Jakarta, 10430, Indonesia; ICTEC (Indonesian Clinical Training and Education Center), Cipto Mangunkusumo Hospital/Faculty of Medicine Universitas Indonesia, Jl. Diponegoro No. 71, Jakarta, 10430, Indonesia; Medical Technology Cluster, IMERI (Indonesian Medical Education and Research Institute), Faculty of Medicine Universitas Indonesia, Education Tower, 2nd Floor, Jl. Salemba Raya No. 6, Jakarta, Indonesia |
Prasetyono, T.O.H., Division of Plastic Surgery, Department of Surgery, Cipto Mangunkusumo Hospital/Faculty of Medicine Universitas Indonesia, Jl. Diponegoro No. 71, Jakarta, 10430, Indonesia, ICTEC (Indonesian Clinical Training and Education Center), Cipto Mangunkusumo Hospital/Faculty of Medicine Universitas Indonesia, Jl. Diponegoro No. 71, Jakarta, 10430, Indonesia, Medical Technology Cluster, IMERI (Indonesian Medical Education and Research Institute), Faculty of Medicine Universitas Indonesia, Education Tower, 2nd Floor, Jl. Salemba Raya No. 6, Jakarta, Indonesia |
One-per-mil epinephrine solution (1:1,000,000) injected as a tumescent has been used in several hand and upper-limb surgery cases as a substitute for tourniquet. However, reviews of its effectiveness are still lacking. A comprehensive review was conducted based on PubMed, Scopus, Science Direct, Cochrane Library, and Semantic Scholar database search of relevant studies using the keyword “one-per-mil.” Studies not using the exact one-per-mil tumescent solution formula were excluded. The review of clinical studies was conducted according to PRISMA guidelines. Epinephrine and the hydrostatic vasocompressive effect created bloodless operative fields, with 100% experimental flap survival after ischemic insult. The technique was effective in creating bloodless operative fields in 36.3% of varied hand and upper-limb surgery cases and in fully awake surgery. Current studies show that one-per-mil tumescent solution is safe and effective, enabling use of tourniquet to be avoided. © 2021 SFCM |
Epinephrine; Hand injury; Lidocaine; Local anesthesia; Wakefulness |
epinephrine; lidocaine; drug solution; hand injury; health care management; human; hydrostatic pressure; local anesthesia; nonhuman; sex difference; Short Survey; therapy effect |
Elsevier Masson s.r.l. |
24681229 |
|
33992818 |
Short Survey |
Q2 |
657 |
7623 |
|
|
|
166 |
Sitohang I.B.S., Sirait S.A.P., Suryanegara J. |
56734569200;24482203600;57204535485; |
Microneedling in the treatment of atrophic scars: A systematic review of randomised controlled trials |
2021 |
International Wound Journal |
18 |
5 |
|
577 |
585 |
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100333569&doi=10.1111%2fiwj.13559&partnerID=40&md5=53a0daf4a5ed46e9fefa3f5918f68c9b |
Department of Dermatology and Venereology, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia |
Sitohang, I.B.S., Department of Dermatology and Venereology, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Sirait, S.A.P., Department of Dermatology and Venereology, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Suryanegara, J., Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia |
To date, treatment of atrophic acne scars remains a therapeutic challenge for dermatologists, yet there is no standard option on the most effective treatment. Microneedling (MN) is a minimally invasive technology that involves repetitive skin puncture using sterile microneedles to disrupt dermal collagen that connects the scar tissue. Recent studies have demonstrated the potency of MN, such as dermaroller and fractionated microneedle radiofrequency, in the treatment of atrophic scars. The objective of this review is to evaluate systematically the current literature on MN for atrophic acne scars. A systematic search of literature was performed from PubMed, Medline, Cochrane Central, and Google Scholar databases for articles published during the last 20 years. Only randomised controlled trials (RCTs) with full-text version of the manuscript available were included in our study. Nine RCTs were included in this review. All treatment modalities demonstrated consistent results that MN was efficacious in treating atrophic acne scars as a monotherapy or in combination with other treatments. Moreover, no serious adverse effects were reported in all studies after MN treatment. MN is a well-tolerated and effective therapeutic modality in treating atrophic acne scars. Further research is required to validate the efficacy of MN with a larger sample size and lengthy follow-up. © 2021 The Authors. International Wound Journal published by Medicalhelplines.com Inc (3M) and John Wiley & Sons Ltd. |
atrophic acne scar; microneedling |
acne vulgaris; atrophy; complication; esthetic surgery; human; needle; pathology; randomized controlled trial (topic); scar; treatment outcome; Acne Vulgaris; Atrophy; Cicatrix; Cosmetic Techniques; Humans; Needles; Randomized Controlled Trials as Topic; Treatment Outcome |
John Wiley and Sons Inc |
17424801 |
|
33538106 |
Article |
Q1 |
867 |
5385 |
|
|
|
167 |
Nunan D., Lindblad A., Widyahening I.S., Bernardo W.M., Chi C.-C., Cowdell F., Becker K., Constantine S., East C., Myrhaug H.T., Johnson S.G., Jack E., Thompson R., Achilleos H., Berg R.C., Snibsøer A.K., Puscasiu L., Bartelink M.-L.E.L., Van Peet P.G., Berti F., Tilson J., Tikkinen K.A.O., Albarqouni L., Hoegen P. |
23976859100;56106404200;54893154400;6507335779;8642372600;8608168300;57219926978;57219929038;57219925201;56503684400;57216536721;57204240840;55763226900;57204277188;24721440500;57193017204;25929536400;6701351200;55270285900;7102391287;23490405400;11142330400;57193204115;57219924120; |
Ten papers for teachers of evidence-based medicine and health care: Sicily workshop 2019 |
2021 |
BMJ Evidence-Based Medicine |
26 |
5 |
|
224 |
227 |
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85096121852&doi=10.1136%2fbmjebm-2020-111479&partnerID=40&md5=f59cb3d2d628fd79e4b11778bafd8318 |
Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom; Centre for Evidence-Based Medicine, University of Oxford, Oxford, United Kingdom; Alberta College of Family Physicians (PEER), The Department of Family Medicine, University of Alberta, Edmonton, AB, Canada; Department of Community Medicine, Faculty of Medicine, Universitas Indonesia, Depok, Indonesia; Faculty of Medicine, University of Sao Paulo, Sao Paulo, Brazil; Department of Dermatology, Chang Gung Memorial Hospital, Taoyuan, Taiwan; College of Medicine, Chang Gung University, Taoyuan, Taiwan; School of Nursing and Midwifery, Faculty of Health, Education and Life Sciences, Birmingham City University, Birmingham, United Kingdom; Family and Social Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, United States; Internal Medicine, Sapporo Tokushukai Hospital, Sapporo, Japan; School of Nursing and Midwifery and Mercy Health, La Trobe University College of Science Health and Engineering, Bundoora, VIC, Australia; Division for Health Sciences, Norwegian Institute of Public Health, Oslo, Norway; Faculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway; Department of Health and Functioning, Faculty of Health and Social Sciences, Western Norway University of Applied Sciences, Bergen, Norway; Yealm Medical Centre, Yealmton, United Kingdom; PenARC (NIHR) Applied Research Collaboration (ARC) South West Peninsula, Exeter, United Kingdom; Office of Medical Education, University of New South Wales, Sydney, NSW, Australia; Paediatrics, Royal London Hospital Barts Health Nhs Trust, London, United Kingdom; Reviews and Health Technology Assessments, Norwegian Institute of Public Health, Oslo, Norway; Health and Caring Sciences, Faculty of Health and Social Sciences, Western Norway University of Applied Sciences, Bergen, Norway; University of Medicine Pharmacy Science and Technology of Targu Mures, Targu Mures, Romania; General Practice, Julius Centre, Umc Utrecht, Utrecht, Netherlands; Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands; Gruppo Italiano per la Medicina Basata Sulle Evidenze (GIMBE), Bologna, Italy; Division of Biokinesiology and Physical Therapy, University of Southern California, Los Angeles, CA, United States; Departments of Urology and Public Health, University of Helsinki, Helsinki University Hospital, Helsinki, Finland; Department of Surgery, South Karelia Central Hospital, Lappeenranta, Finland; Institute for Evidence-Based Healthcare, Faculty of Health Sciences and Medicine, Bond University, Gold Coast, QLD, Australia; School of Health and Social Care, Avans University of Applied Science, Breda, Netherlands |
Nunan, D., Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom, Centre for Evidence-Based Medicine, University of Oxford, Oxford, United Kingdom; Lindblad, A., Alberta College of Family Physicians (PEER), The Department of Family Medicine, University of Alberta, Edmonton, AB, Canada; Widyahening, I.S., Department of Community Medicine, Faculty of Medicine, Universitas Indonesia, Depok, Indonesia; Bernardo, W.M., Faculty of Medicine, University of Sao Paulo, Sao Paulo, Brazil; Chi, C.-C., Department of Dermatology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, College of Medicine, Chang Gung University, Taoyuan, Taiwan; Cowdell, F., School of Nursing and Midwifery, Faculty of Health, Education and Life Sciences, Birmingham City University, Birmingham, United Kingdom; Becker, K., Family and Social Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, United States; Constantine, S., Internal Medicine, Sapporo Tokushukai Hospital, Sapporo, Japan; East, C., School of Nursing and Midwifery and Mercy Health, La Trobe University College of Science Health and Engineering, Bundoora, VIC, Australia; Myrhaug, H.T., Division for Health Sciences, Norwegian Institute of Public Health, Oslo, Norway, Faculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway; Johnson, S.G., Department of Health and Functioning, Faculty of Health and Social Sciences, Western Norway University of Applied Sciences, Bergen, Norway; Jack, E., Yealm Medical Centre, Yealmton, United Kingdom, PenARC (NIHR) Applied Research Collaboration (ARC) South West Peninsula, Exeter, United Kingdom; Thompson, R., Office of Medical Education, University of New South Wales, Sydney, NSW, Australia; Achilleos, H., Paediatrics, Royal London Hospital Barts Health Nhs Trust, London, United Kingdom; Berg, R.C., Reviews and Health Technology Assessments, Norwegian Institute of Public Health, Oslo, Norway; Snibsøer, A.K., Health and Caring Sciences, Faculty of Health and Social Sciences, Western Norway University of Applied Sciences, Bergen, Norway; Puscasiu, L., University of Medicine Pharmacy Science and Technology of Targu Mures, Targu Mures, Romania; Bartelink, M.-L.E.L., General Practice, Julius Centre, Umc Utrecht, Utrecht, Netherlands; Van Peet, P.G., Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands; Berti, F., Gruppo Italiano per la Medicina Basata Sulle Evidenze (GIMBE), Bologna, Italy; Tilson, J., Division of Biokinesiology and Physical Therapy, University of Southern California, Los Angeles, CA, United States; Tikkinen, K.A.O., Departments of Urology and Public Health, University of Helsinki, Helsinki University Hospital, Helsinki, Finland, Department of Surgery, South Karelia Central Hospital, Lappeenranta, Finland; Albarqouni, L., Institute for Evidence-Based Healthcare, Faculty of Health Sciences and Medicine, Bond University, Gold Coast, QLD, Australia; Hoegen, P., School of Health and Social Care, Avans University of Applied Science, Breda, Netherlands |
[No abstract available] |
evidence-based practice; health; patient care |
consensus; Delphi study; ethnographic research; evidence based medicine; evidence based practice; health care; health practitioner; human; interview; knowledge management; medical education; patient; patient care; physician; practice guideline; primary medical care; publication; Review; risk factor; risk reduction; shared decision making; Sicily; systematic review (topic); teacher; workshop; health care delivery; Delivery of Health Care; Evidence-Based Medicine; Humans; Sicily |
BMJ Publishing Group |
2515446X |
|
33172938 |
Review |
Q2 |
676 |
7397 |
|
|
|
168 |
Andriyati R., Firman D., Kurniawati Y., Alkatiri A.A., Pranata R., Muliawan H.S., Rossimarina V., Soerianata S. |
57219712507;54898724100;57199153189;57210302708;57201973901;57203644653;57219708502;6504387197; |
Improved clinical outcome with biodegradable polymer drug-eluting stents compared to durable polymer drug-eluting stents for primary percutaneous coronary intervention |
2021 |
Postgraduate Medical Journal |
97 |
1152 |
|
638 |
643 |
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85094912557&doi=10.1136%2fpostgradmedj-2020-138243&partnerID=40&md5=10b39bd26552fd6e6283165f7c0afe78 |
Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia |
Andriyati, R., Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Firman, D., Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Kurniawati, Y., Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Alkatiri, A.A., Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Pranata, R., Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia; Muliawan, H.S., Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Rossimarina, V., Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Soerianata, S., Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia |
Background Studies comparing the clinical outcomes of second-generation biodegradable polymer drug-eluting stents (BP-DES) and second-generation durable polymer drug-eluting stents (DP-DES) in patients with ST-segment elevation myocardial infarction (STEMI) with follow-up duration of more than 1 year are still limited. Objective This study aimed to compare the 2-year clinical outcome of BP-DES with second-generation DP-DES in patients undergoing primary percutaneous coronary intervention (PPCI). Methods This is a retrospective cohort study in patients with STEMI, the primary endpoint was major adverse cardiac events (MACE) defined as recurrent myocardial infarction, total repeat revascularisation and cardiac death. The secondary endpoint was stent thrombosis (ST) defined as definite, probable or possible. Results A total of 400 patients were analysed (197 BP-DES groups and 203 DP-DES groups). BP-DES were independently associated with lower incidence of MACE (adjusted HR 0.67, 95% CI 0.21 to 0.91, p=0.005) and ST (adjusted HR 0.62, 95% CI 0.19 to 0.73, p<0.016) within 2 years of follow-up. Subgroup analysis of MACE individual components showed that BP-DES were associated with lower cardiac deaths (HR 0.35; 95% CI 0.18 to 0.94; p<0.001) compared to DP-DES, but not recurrent myocardial infarction and total repeat revascularisation. Conclusions BP-DES were associated with better clinical outcomes compared to second-generation DP-DES in patients with STEMI undergoing PPCI. © |
adult cardiology; Cardiology; coronary heart disease; coronary intervention; ischaemic heart disease; myocardial infarction |
acetylsalicylic acid; beta adrenergic receptor blocking agent; clopidogrel; creatinine; glucose; hydroxymethylglutaryl coenzyme A reductase inhibitor; ticagrelor; troponin I; troponin T; polymer; acute heart infarction; adult; Article; chronic kidney failure; clinical outcome; cohort analysis; controlled clinical trial; controlled study; coronary angiography; diabetes mellitus; diastolic blood pressure; dual antiplatelet therapy; dyslipidemia; female; fibrinolytic therapy; heart death; heart infarction; heart left ventricle ejection fraction; heart rate; human; hypertension; incidence; major adverse cardiac event; major clinical study; male; middle aged; mortality; non ST segment elevation myocardial infarction; observational study; percutaneous coronary intervention; retrospective study; |
BMJ Publishing Group |
00325473 |
|
32796116 |
Article |
Q2 |
568 |
8912 |
|
|
|
169 |
Anita N., Abinawanto, Jusuf A.A., Bowolaksono A., Saoemi H.A. |
57211777639;57285890300;57192275719;57205093224;57215011193; |
Effect of ethylene glycol on structural integrity at each stage of preantral follicle development post vitrification of rat ovary-histological analysis |
2021 |
HAYATI Journal of Biosciences |
28 |
4 |
|
304 |
311 |
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85119020921&doi=10.4308%2fHJB.28.4.304-311&partnerID=40&md5=9e167a2dec7b6cf26ee525beea150963 |
Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Indonesia, Depok, Indonesia; Cellular and Molecular Mechanism in Biological System Research Group, Department of Biology, Universitas Indonesia, Depok, Indonesia; Department of Histology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Master’s Programme in Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia |
Anita, N., Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Indonesia, Depok, Indonesia, Cellular and Molecular Mechanism in Biological System Research Group, Department of Biology, Universitas Indonesia, Depok, Indonesia; Abinawanto, Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Indonesia, Depok, Indonesia; Jusuf, A.A., Department of Histology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Bowolaksono, A., Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Indonesia, Depok, Indonesia; Saoemi, H.A., Master’s Programme in Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia |
The structure of follicular tissue affects the ability to maintain the structural integrity of follicles against cryoinjury post-vitrification. Histological analysis was conducted on the structural integrity of each stage of preantral follicles post-vitrification using 7.5% and 15.0% doses of ethylene glycol (EG), and ovarian sections with HE staining were observed using an Olympus CX21 microscope connected to Optilab 3.0 lens and Image Raster software. Analysis was conducted on the ovarian cortex in the tracing line area using polygon measure tools to obtain follicle density (follicles/mm2) and follicle index (%) data. The result showed that the EG group 7.5% (KP1) increased follicle density compared to the vitrified group (KKV) in primordial (15.83±1.77) and primary (22.94±8.51) stages. Meanwhile, KP2 (EG 15%) was in primordial (41.92±6.45), primary (11.69±1.95), secondary (33.48±3.63), and tertiary (5.93±0.69) stages. KP1 increased grade 3 follicle index compared to KKV in primary (27.66±2.34), secondary (32.41±6.99), and tertiary (25.00±5.00) stages. Meanwhile, KP2 was in primary (26.87±6.68) and tertiary (25.00±5.00) stages. Both doses of 7.5% and 15.0% EG were able to maintain structural integrity at certain stages of preantral follicles. Secondary and tertiary follicles are the best stages in maintaining grade 3 follicular integrity with the addition of 7.5% EG. ©2021 Institut Pertanian Bogor. |
Cryoinjury; Follicle density; Follicle index; Grading method; Preservation |
|
Bogor Agricultural University |
19783019 |
|
|
Article |
Q2 |
305 |
14644 |
|
|
|
172 |
Mustika S., Pratama M.Z., Lesmana C.R.A. |
37063469000;56993540600;8977683000; |
Diagnostic challenge in a patient presenting with ascites and hypergammaglobulinemia |
2021 |
Case Reports in Gastroenterology |
15 |
3 |
|
810 |
818 |
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85116089151&doi=10.1159%2f000518384&partnerID=40&md5=abcdfe47d8eee85899e25c7644e30957 |
Gastroenterohepatology Division, Department of Internal Medicine, Faculty of Medicine Universitas Brawijaya, Saiful Anwar General Hospital, Malang, Indonesia; Hepatobiliary Division, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia |
Mustika, S., Gastroenterohepatology Division, Department of Internal Medicine, Faculty of Medicine Universitas Brawijaya, Saiful Anwar General Hospital, Malang, Indonesia; Pratama, M.Z., Gastroenterohepatology Division, Department of Internal Medicine, Faculty of Medicine Universitas Brawijaya, Saiful Anwar General Hospital, Malang, Indonesia; Lesmana, C.R.A., Hepatobiliary Division, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia |
Ascites is defined as the accumulation of intra-peritoneal fluid that can be caused by several diseases. We described a 47-year-old female presenting with low serum-ascites albumin gradient (SAAG) and a markedly high level of serum globulin. Serum protein electrophoresis revealed an M spike in the gamma region. Other laboratory results showed a marked increase in aspartate aminotransferase and alanine aminotransferase and predominantly conjugated hyperbilirubinemia without a sign of dilatation of bile ducts from abdominal ultrasonography examination. Furthermore, the follow-up showed a positive result for the anti-nuclear antibody test. The patient was assessed with autoimmune hepatitis, and the cause of ascites was suggested from portal hypertension although the level of SAAG was low. The ascites condition got improved after salt restriction, diuretics treatment, and abdominal paracentesis. However, the patient passed away because of the intracranial hemorrhage as a result of prolonged INR and APTT due to liver failure. © 2021 |
Ascites; Autoimmune hepatitis; Hypergammaglobulinemia |
alanine aminotransferase; albumin; alkaline phosphatase; antinuclear antibody; aspartate aminotransferase; bilirubin; creatinine; diuretic agent; furosemide; gamma glutamyltransferase; lactate dehydrogenase; prednisone; serum globulin; spironolactone; triacylglycerol; urobilinogen; ursodeoxycholic acid; abdominal circumference; activated partial thromboplastin time; adult,human; Article; ascites; autoimmune hepatitis; bile duct dilatation; body weight loss; bone marrow biopsy; brain hemorrhage; case report; echography; enzyme linked immunosorbent assay; female; follow up; gastrointestinal hemorrhage; human; human tissue; human,clinical article; hyperbilirubinemia; hypergammaglobulinemia; international normalized ratio; jaundice; leg swelling; leukocytosis; liver failure; liver function tes |
S. Karger AG |
16620631 |
|
|
Article |
Q3 |
247 |
16829 |
|
|
|
173 |
Forrat R., Dayan G.H., DiazGranados C.A., Bonaparte M., Laot T., Capeding M.R., Sanchez L., Coronel D.L., Reynales H., Chansinghakul D., Hadinegoro S.R.S., Perroud A.P., Frago C., Zambrano B., Machabert T., Wu Y., Luedtke A., Price B., Vigne C., Haney O., Savarino S.J., Bouckenooghe A., Noriega F. |
36339272700;6701860993;56721307400;56614799700;24471016000;6602161242;57201082261;56418742600;55343075300;29067671300;56893685800;57198777256;56255310300;7801355579;57201364463;57215829074;54395741500;57002517700;57192890936;57215866119;57220410062;18233281300;7005980306; |
Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America |
2021 |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |
73 |
6 |
|
1003 |
1012 |
|
1 |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85116958578&doi=10.1093%2fcid%2fciab288&partnerID=40&md5=cceec1a946e6b236b138dcb4bb663855 |
Clinical Sciences, Sanofi Pasteur, Marcy l'Etoile, France; Clinical Sciences Sanofi PasteurPA, United States; Translation Sciences and Biomarkers, Sanofi PasteurPA, United States; Global Clinical Science, Sanofi Pasteur, Taguig City, Philippines; Research Institute for Tropical Medicine, Medical Department, Muntinlupa, Philippines; Clinical Sciences, Sanofi PasteurMexico City, Mexico; Centro de Atencion e Investigación Médica, Bogotá, Colombia; Research & Development, Sanofi PasteurBangkok, Thailand; Cipto Mangunkusumo Hospital, University of IndonesiaJakarta, Indonesia; Clinical Sciences, Sanofi Pasteur, São Paulo, Brazil; Clinical Sciences, Sanofi Pasteur, Singapore; Clinical Sciences, Sanofi Pasteur, Uruguay; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States; Global Pharmacovigilance, Sanofi PasteurPA, United States |
Forrat, R., Clinical Sciences, Sanofi Pasteur, Marcy l'Etoile, France; Dayan, G.H., Clinical Sciences Sanofi PasteurPA, United States; DiazGranados, C.A., Clinical Sciences Sanofi PasteurPA, United States; Bonaparte, M., Translation Sciences and Biomarkers, Sanofi PasteurPA, United States; Laot, T., Global Clinical Science, Sanofi Pasteur, Taguig City, Philippines; Capeding, M.R., Research Institute for Tropical Medicine, Medical Department, Muntinlupa, Philippines; Sanchez, L., Global Clinical Science, Sanofi Pasteur, Taguig City, Philippines; Coronel, D.L., Clinical Sciences, Sanofi PasteurMexico City, Mexico; Reynales, H., Centro de Atencion e Investigación Médica, Bogotá, Colombia; Chansinghakul, D., Research & Development, Sanofi PasteurBangkok, Thailand; Hadinegoro, S.R.S., Cipto Mangunkusumo Hospital, University of IndonesiaJakarta, Indonesia; Perroud, A.P., Clinical Sciences, Sanofi Pasteur, São Paulo, Brazil; Frago, C., Clinical Sciences, Sanofi Pasteur, Singapore; Zambrano, B., Clinical Sciences, Sanofi Pasteur, Uruguay; Machabert, T., Clinical Sciences, Sanofi Pasteur, Marcy l'Etoile, France; Wu, Y., Clinical Sciences Sanofi PasteurPA, United States; Luedtke, A., Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States; Price, B., Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States; Vigne, C., Clinical Sciences, Sanofi Pasteur, Marcy l'Etoile, France; Haney, O., Global Pharmacovigilance, Sanofi PasteurPA, United States; Savarino, S.J., Translation Sciences and Biomarkers, Sanofi PasteurPA, United States; Bouckenooghe, A., Clinical Sciences, Sanofi Pasteur, São Paulo, Brazil; Noriega, F., Clinical Sciences Sanofi PasteurPA, United States |
BACKGROUND: CYD-TDV, a live, attenuated, tetravalent dengue vaccine, has been approved for the prevention of symptomatic dengue in previously dengue exposed individuals. This post hoc analysis assessed hospitalized and severe virologically confirmed dengue (VCD) over the complete 6-year follow-up of 3 CYD-TDV efficacy studies (CYD14, CYD15, and CYD23/CYD57). METHODS: The main outcomes were hazard ratios (HRs) for hospitalized or severe VCD by baseline dengue serostatus, focusing on those who were seropositive, and by age at immunization (<9 years/≥9 years). Baseline dengue serostatus was measured or inferred using several methods. Hospitalized VCD cases were characterized in terms of clinical signs and symptoms and wild-type viremia level. Antibody persistence was assessed up to 5 years after the last injection. RESULTS: In those aged ≥9 years and baseline seropositive, CYD-TDV protected against hospitalized and severe VCD over 6 years compared to placebo (HR [95% confidence interval] multiple imputation from month 0 method, .19 [.12-.30] and .15 [.06-.39]; other methods were consistent). Vaccine protection was observed over the different study periods, being highest during the first 2 years. Evidence for a decreased risk of hospitalized and severe VCD was also observed in seropositive participants aged 6-8 years. Clinical signs and symptoms, and quantified dengue viremia from participants with hospitalized VCD were comparable between groups. CONCLUSIONS: CYD-TDV demonstrated robust protection against hospitalized and severe VCD over the entire 6-year follow-up in participants who were seropositive and ≥9 years old. Protection was also observed in seropositive 6-8 year-olds. Clinical Trials Registration: NCT00842530, NCT01983553, NCT01373281, NCT01374516. © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. |
CYD-TDV; dengue; serostatus; VCD |
dengue vaccine; live vaccine; vaccine; virus antibody; Asia; child; controlled study; dengue; Dengue virus; follow up; human; randomized controlled trial; severe dengue; South and Central America; Antibodies, Viral; Asia; Child; Dengue; Dengue Vaccines; Dengue Virus; Follow-Up Studies; Humans; Latin America; Severe Dengue; Vaccines, Attenuated; Vaccines, Combined |
NLM (Medline) |
15376591 |
|
33822015 |
Article |
Q1 |
3440 |
518 |
|
|
|
177 |
Karina K., Ekaputri K., Albert Biben J., Rosadi I., Rosliana I., Sobariah S., Sulaeha A.D., Andrew H., Afini I., Widyastuti T., Jusryanti J., Prestiani S.I., Donna I.M., Mutiara M.S., Habibi H. |
57212146678;57285088000;57284643500;57204720098;57186671400;57203547382;57226286645;57226282534;57211068324;57211074403;57284643600;57283770100;57284210300;57284210400;57222314524; |
Evaluation of plasma pdgf and vegf levels after systemic administration of activated autologous platelet-rich plasma |
2021 |
Biomedicine (India) |
41 |
|
|
409 |
412 |
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85116318936&doi=10.51248%2f.v41i2.1047&partnerID=40&md5=b63a888f3eb59bb12b87fdd1bfa4f091 |
Klinik Hayandra, Yayasan Hayandra Peduli, Jl. Kramat VI No. 11, Jakarta Pusat, 10430, Indonesia; Hayandra Lab, Yayasan Hayandra Peduli, Jl. Kramat VI No. 11, Jakarta Pusat, 10430, Indonesia; Faculty of Medicine, Universitas Pembangunan Nasional Veteran, Jakarta, 12450, Indonesia; Pusat Kajian Stem Cell, Universitas Pembangunan Nasional Veteran, Jakarta, 12450, Indonesia; Department of Biology, Faculty of Mathematics and Natural Sciences, Mulawarman University, Samarinda, 752424, Indonesia; Faculty of Medicine, Universitas Indonesia, Jl. Salemba Raya no. 6, Jakarta Pusat, 10430, Indonesia |
Karina, K., Klinik Hayandra, Yayasan Hayandra Peduli, Jl. Kramat VI No. 11, Jakarta Pusat, 10430, Indonesia, Hayandra Lab, Yayasan Hayandra Peduli, Jl. Kramat VI No. 11, Jakarta Pusat, 10430, Indonesia, Faculty of Medicine, Universitas Pembangunan Nasional Veteran, Jakarta, 12450, Indonesia, Pusat Kajian Stem Cell, Universitas Pembangunan Nasional Veteran, Jakarta, 12450, Indonesia; Ekaputri, K., Klinik Hayandra, Yayasan Hayandra Peduli, Jl. Kramat VI No. 11, Jakarta Pusat, 10430, Indonesia; Albert Biben, J., Klinik Hayandra, Yayasan Hayandra Peduli, Jl. Kramat VI No. 11, Jakarta Pusat, 10430, Indonesia; Rosadi, I., Hayandra Lab, Yayasan Hayandra Peduli, Jl. Kramat VI No. 11, Jakarta Pusat, 10430, Indonesia, Department of Biology, Faculty of Mathematics and Natural Sciences, Mulawarman University, Samarinda, 752424, Indonesia; Rosliana, I., Hayandra Lab, Yayasan Hayandra Peduli, Jl. Kramat VI No. 11, Jakarta Pusat, 10430, Indonesia; Sobariah, S., Hayandra Lab, Yayasan Hayandra Peduli, Jl. Kramat VI No. 11, Jakarta Pusat, 10430, Indonesia; Sulaeha, A.D., Klinik Hayandra, Yayasan Hayandra Peduli, Jl. Kramat VI No. 11, Jakarta Pusat, 10430, Indonesia; Andrew, H., Hayandra Lab, Yayasan Hayandra Peduli, Jl. Kramat VI No. 11, Jakarta Pusat, 10430, Indonesia, Faculty of Medicine, Universitas Indonesia, Jl. Salemba Raya no. 6, Jakarta Pusat, 10430, Indonesia; Afini, I., Hayandra Lab, Yayasan Hayandra Peduli, Jl. Kramat VI No. 11, Jakarta Pusat, 10430, Indonesia; Widyastuti, T., Hayandra Lab, Yayasan Hayandra Peduli, Jl. Kramat VI No. 11, Jakarta Pusat, 10430, Indonesia; Jusryanti, J., Klinik Hayandra, Yayasan Hayandra Peduli, Jl. Kramat VI No. 11, Jakarta Pusat, 10430, Indonesia; Prestiani, S.I., Klinik Hayandra, Yayasan Hayandra Peduli, Jl. Kramat VI No. 11, Jakarta Pusat, 10430, Indonesia; Donna, I.M., Klinik Hayandra, Yayasan Hayandra Peduli, Jl. Kramat VI No. 11, Jakarta Pusat, 10430, Indonesia; Mutiara, M.S., Klinik Hayandra, Yayasan Hayandra Peduli, Jl. Kramat VI No. 11, Jakarta Pusat, 10430, Indonesia; Habibi, H., Klinik Hayandra, Yayasan Hayandra Peduli, Jl. Kramat VI No. 11, Jakarta Pusat, 10430, Indonesia |
Introduction and Aim: Activated autologous platelet-rich plasma (aaPRP) is becoming a popular therapy to accelerate healing in the field of plastic surgery. Platelets, which are abundant in aaPRP, can release many growth factors including platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF). This study aims to examine the plasma levels of PDGF and VEGF in healthy subjects after intravenous administration of aaPRP. Materials and Methods: Nine healthy patients with no prior history of metabolic disease were divided into two groups (control and experiment group). The treatment group which consists of six patients received intravenous aaPRP treatment. The preparation of aaPRP starts with the collection of 24 mL of whole blood in sodium citrate tubes followed a two-step centrifugation procedure and subsequent chemical activation. aaPRP was then administered intravenously to patients. Meanwhile, the control group received no intervention. Venous blood samples were taken before and one week after the treatment and the plasma PDGF and VEGF levels were determined by enzyme-linked immunosorbent assay (ELISA). Results: The treatment group showed statistically significant increase in VEGF after 7 days compared to before aaPRP administration. However, the change in PDGF levels of the treatment group was unnotable. Conclusion: The present findings indicate that intravenous administrations of activated aaPRP may increase plasma VEGF level up to 1 week after aaPRP administration. © 2021, Indian Association of Biomedical Scientists. All rights reserved. |
Activated autologous platelet-rich plasma (aaPRP); Platelet derived growth factor (PDGF); Vascular endothelial growth factor (VEGF) |
activated autologous platelet rich plasma; citrate sodium; platelet derived growth factor; thrombocyte concentrate; unclassified drug; vasculotropin; adult; Article; blood autotransfusion; blood chemistry; blood sampling; case control study; centrifugation; cohort analysis; controlled study; enzyme linked immunosorbent assay; female; human; human cell; male; metabolic disorder; middle aged; observational study; prospective study; protein blood level; thrombocyte rich plasma; venous blood |
Indian Association of Biomedical Scientists |
09702067 |
|
|
Article |
Q4 |
106 |
29384 |
|
|
|
179 |
Gamalliel N., Saminarsih D., Taher A. |
57222183873;57223010643;7005269743; |
Indonesia's second wave crisis: medical doctors' political role is needed more than ever |
2021 |
The Lancet |
398 |
10303 |
|
839 |
840 |
|
1 |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85114086978&doi=10.1016%2fS0140-6736%2821%2901807-9&partnerID=40&md5=ee813e67f093a1a11797cba6ffb2072e |
Faculty of Medicine, Universitas Indonesia, Jakarta, 10430, Indonesia; Department of Urology, Cipto Mangunkusumo Hospital, Universitas Indonesia, Jakarta, 10430, Indonesia; World Health Organization, Geneva, Switzerland |
Gamalliel, N., Faculty of Medicine, Universitas Indonesia, Jakarta, 10430, Indonesia; Saminarsih, D., World Health Organization, Geneva, Switzerland; Taher, A., Department of Urology, Cipto Mangunkusumo Hospital, Universitas Indonesia, Jakarta, 10430, Indonesia |
[No abstract available] |
|
SARS-CoV-2 vaccine; coronavirus disease 2019; discourse analysis; disease transmission; health care delivery; health care need; health care planning; health care policy; health care system; human; Indonesia; Letter; physician attitude; population health; vaccination; Indonesia; patient advocacy; physician; politics; COVID-19; Humans; Indonesia; Patient Advocacy; Physicians; Politics |
Elsevier B.V. |
01406736 |
|
34384538 |
Letter |
#N/A |
#N/A |
#N/A |
|
|
